Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC).
Kashima S, Xu W, Canniff J, Saliby R, Sun M, Lee G, Machaalani M, Signoretti S, McGregor B, McKay R, Choueiri T, Braun D. Comprehensive proteomic profiling of plasma samples associated with response or resistance to immune checkpoint inhibitors (ICI) in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43: 562-562. DOI: 10.1200/jco.2025.43.5_suppl.562.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaRenal cell carcinoma patientsICI-based therapyNon-respondersPatients treated with ICI monotherapyResistance to immune checkpoint inhibitorsHLA-BICI respondersAdvanced renal cell carcinomaImmune cells to tumorsTGF-B pathwayTreatment evolutionCells to tumorsSustained immune activationPlasma samplesProfiling of plasma samplesCornerstone of treatmentPaired samplesPlasma proteomic analysisAssociated with responseAnti-tumor inflammationICI monotherapyInvestigated plasma proteinsCheckpoint inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply